CN113350451A

CN113350451A - Use of pharmaceutical composition for preparing medicine for treating intraocular pressure

Info

Publication number: CN113350451A
Application number: CN202010137081.5A
Authority: CN
Inventors: 张腾龙
Original assignee: Individual
Current assignee: Individual
Priority date: 2020-03-02
Filing date: 2020-03-02
Publication date: 2021-09-07

Abstract

The invention relates to an application of a pharmaceutical composition in preparing a medicine for treating intraocular pressure, which replaces traditional western medicines with natural substances such as medlar powder, chrysanthemum powder, mulberry powder, red algae powder, corn stigma, zinc gluconate, selenium yeast, bitter tea oil, vitamin A, marigold powder and the like to relieve intraocular pressure rise (induced by an LED lamp) and further relieve the symptom of intraocular pressure excess.

Description

Use of pharmaceutical composition for preparing medicine for treating intraocular pressure

Technical Field

The invention relates to a pharmaceutical composition, in particular to an application of the pharmaceutical composition in preparing a medicine for treating intraocular pressure.

Background

The eye is the organ of vision responsible for receiving light from the environment and producing vision. In the process of forming vision, light firstly passes through the transparent cornea and the crystal in the eye, and by means of the light-gathering function of the two structures, the light can be focused on the retina to form an image, and the light-sensitive cells in the retina are stimulated to convert light stimulation into electric signals, and the electric signals reach the brain vision area through the conduction of optic nerves, and the vision is formed under the signal processing of the nerve cells.

However, with the rapid development of modern technologies, in addition to the rapid mass production of 3C products (mobile phones, tablet computers, desk computers …, etc.), the time for using 3C products is also increasing. Thus, the incidence of eye-related disorders (dry eye, myopia, ocular hypertension, glaucoma …, etc.) also increases and the incidence of age decreases year by year.

In order to prevent any disorder of the eye, a number of different methods of soothing the eye have been proposed. For example, the patient may temporarily close the eyes for rest, look far away, massage the eyes, wear sunglasses, and take vitamins and eye drops …. However, once the eye diseases are detected, except for the diseases needing surgical treatment, most of the eye diseases are treated by using medicines, but the medicines have certain side effects.

In the case of ocular hypertension, it is usually necessary for the eye to maintain a certain shape by having a certain pressure in the eye, i.e. intraocular pressure, which is maintained in a constant range by the aqueous humor secreted by the ciliary body, normally secreted into the posterior chamber of the eye, passed through the pupil to the anterior chamber, and then expelled out of the eye through the trabecular tissue of the corner of the anterior chamber.

If too much aqueous humor is generated or a drainage system is blocked, so that the aqueous humor is accumulated in the eyeball to be too much, the pressure begins to rise, the intraocular pressure is too high, if the intraocular pressure rises to a certain degree, the optic nerve is initially pressed to atrophy the optic nerve, the peripheral visual field cannot be seen firstly and then the vision gradually declines along with the gradual atrophy of the optic nerve, and finally the blindness is caused by the complete atrophy of the optic nerve.

In addition to excessive aqueous humor accumulation, ocular hypertension is also easily caused by high myopia, long-term use of steroid eye drops, and systemic diseases. In the case of high myopia, the ocular axis of the patient becomes longer, resulting in a relatively smaller anterior chamber space, and thus, the phenomenon of high intraocular pressure is more likely to occur.

Furthermore, according to the medical statistics in the past, when the steroid-containing eye drops are used for a long time (more than 1 month), the intraocular pressure is increased in 10% of people; if the myopia is high (more than 500 degrees), glaucoma is more likely to occur (40% of the time), and the increase in intraocular pressure is 39 times higher than that of the normal people. The systemic diseases, such as diabetes and cardiovascular diseases …, can also cause high intraocular pressure in later complications.

At present, there are many drugs for treating ocular hypertension, including 1. beta-sympathetic blocking agents, 2. alpha.2-sympathetic agonists, and 3. prostaglandin derivatives ….

1. Beta-sympathetic nerve blocking agent, which can reduce the secretion of aqueous humor and has obvious effect of reducing intraocular pressure, is the first line drug at present. However, the main side effects are eye irritation, conjunctivitis and keratitis. In addition, systemic side effects such as slow heartbeat, irregular heart rhythm, dizziness, asthma attack may be present through mucosal absorption.

2. Alpha 2-sympathetic agonists, which reduce aqueous humor secretion and increase aqueous humor outflow from the uveoscleral pathway to lower intraocular pressure, are useful as alternatives to beta-sympathetic blockers. But its major side effects are allergic conjunctivitis, conjunctival congestion, eye itching, burning sensation, blurred vision, dry mouth.

3. Prostaglandin derivatives (such as sulbactam) which can increase the drainage of aqueous humor from the uveoscleral pathway to lower intraocular pressure, and can be used only once a day due to long drug effect and good pressure-lowering effect. But still have its side effects such as blurred vision, conjunctival congestion, eye itching, dry eye, keratitis, periocular pigmentation, eyelash proliferation and darkening of color (which is irregular proliferation that may cause the eyelashes to be inserted upside down and to recover after withdrawal of the drug), macular edema, iriditis, photophobia, etc.

Therefore, as can be seen from the above, although the existing drugs can treat the condition of ocular hypertension, certain side effects still exist, and regarding eye related diseases, the prevention is often better than the treatment, so that the effective components needed for preventing the eye diseases are usually recommended to be obtained from diet or health food.

Therefore, it is a problem to be solved by those skilled in the art to prevent the occurrence of eye disorders (e.g., ocular hypertension …, etc.), to improve the daily maintenance of eyes, to extract effective components from natural diet, and to prepare them.

Disclosure of Invention

The main purpose of the present invention is to provide an application of a pharmaceutical composition for preparing a medicine for treating intraocular pressure, wherein natural substances such as wolfberry powder, chrysanthemum powder, mulberry powder, red algae powder, corn stigma powder, zinc gluconate, selenium yeast, bitter tea oil, vitamin A and marigold powder are used to alleviate intraocular pressure increase (induced by an LED lamp) and further alleviate symptoms of intraocular pressure increase.

In order to achieve the purpose and the effect, the invention discloses application of a pharmaceutical composition in preparing a medicine for treating intraocular pressure, wherein the pharmaceutical composition comprises wolfberry powder, chrysanthemum powder, mulberry powder, red algae powder, corn stigma powder, zinc gluconate, selenium yeast, bitter tea oil, vitamin A and Chinese holly powder, and the pharmaceutical composition is used for relieving symptoms of the intraocular pressure.

The present invention provides an embodiment consisting in the use of a pharmaceutical composition for the preparation of a medicament for the treatment of intraocular pressure, wherein the pharmaceutical composition further comprises a cocoa powder, a microcrystalline cellulose and a magnesium stearate.

The present invention provides an embodiment consisting in the use of a pharmaceutical composition for the preparation of a medicament for the treatment of intraocular pressure, wherein the marigold powder further comprises a xanthophyll.

The present invention provides an embodiment, which is the use of a pharmaceutical composition for the preparation of a medicament for treating intraocular pressure, wherein the powder of Morus bombycis further comprises an anthocyanin.

The present invention provides an embodiment consisting in the use of a pharmaceutical composition for the preparation of a medicament for the treatment of intraocular pressure, wherein the red algae powder further comprises a prawnin.

The present invention provides an embodiment consisting in the use of a pharmaceutical composition for the preparation of a medicament for the treatment of intraocular pressure, wherein the pharmaceutical composition is for alleviating an increase in intraocular pressure.

The present invention provides an embodiment consisting in the use of a pharmaceutical composition for the preparation of a medicament for the treatment of intraocular pressure, wherein the increase in intraocular pressure is induced by an LED lamp.

Drawings

FIG. 1A: it is a schematic diagram of the variation of intraocular pressure according to an embodiment of the present invention

FIG. 1B: which is a detailed result diagram of intraocular pressure changes in one embodiment of the present invention; and

FIG. 2: which is a bar graph illustrating intraocular pressure according to various experimental conditions in one embodiment of the present invention.

Detailed Description

In order to provide a further understanding and appreciation for the structural features and advantages achieved by the present invention, the following detailed description of the presently preferred embodiments is provided:

when the intraocular pressure of the human body is too high, usually, in order to maintain a certain shape, a certain pressure is necessary to exist in the eye, namely, the intraocular pressure, and the maintenance of the intraocular pressure in a constant range is achieved by means of aqueous humor secreted by ciliary bodies, and normally, the aqueous humor is secreted into the posterior chamber of the eye, flows through the pupil to reach the anterior chamber, and is discharged out of the eye through trabecular tissues at the corners of the anterior chamber.

Currently, there are many drugs for treating ocular hypertension, including β -sympathetic blockers, α 2-sympathetic effectors, and prostaglandin derivatives ….

However, the above drugs cause side effects, such as the β -sympathetic nerve blocking agent causes side effects in human body: slow heartbeat, irregular heart rhythm, dizziness, asthma attack, or alpha 2-sympathetic effectors cause side effects in humans: allergic conjunctivitis, conjunctival congestion, ocular itching, burning sensation, blurred vision, dry mouth, or side effects caused by prostaglandin derivatives: blurred vision, conjunctival congestion, eye itching, dry eye, keratitis, periocular pigmentation, eyelash proliferation and darkening (which is irregular proliferation and may cause the eyelashes to be inserted upside down and to recover after stopping administration), macular edema, iriditis, photophobia, etc.

In view of the influence of certain side effects of the traditional western medicine of eyes. Accordingly, the present invention provides a use of a pharmaceutical composition for preparing a medicament for treating intraocular pressure, so as to solve the problems caused by the prior art.

The invention further includes features, associated structures and methods that are described in the following:

the invention discloses application of a pharmaceutical composition in preparing a medicine for treating intraocular pressure, wherein the pharmaceutical composition comprises a wolfberry fruit powder, a chrysanthemum flower powder, a mulberry fruit powder, a red algae powder, a corn stigma powder, zinc gluconate, selenium yeast, bitter tea oil, vitamin A and longlife inulin.

EXAMPLE 1 composition of pharmaceutical composition

Firstly, the composition proportion in the medicine composition is that the medlar powder is 37.5%, the chrysanthemum powder is 31.25%, the mulberry powder is 2.5%, the red algae powder is 0.5%, the corn stigma powder is 0.5%, the zinc gluconate is 0.25%, the selenium yeast is 0.25%, the vitamin A content is 0.03%, the marigold powder is 0.025% and the bitter tea oil is prepared according to the proportion.

Preparation of fructus Lycii powder (also flos Chrysanthemi powder or fructus Mori powder or fructus Jujubae powder or flos Tagetis Erectae powder)

Drying the wolfberry fruit (also the chrysanthemum, the hill mulberry, the red algae or the marigold), standing, cooling to room temperature, and crushing the wolfberry fruit (also the chrysanthemum, the hill mulberry, the red algae or the marigold) by using a grinding device to obtain wolfberry fruit powder (also chrysanthemum powder, hill mulberry powder, red algae powder or marigold powder).

Preparation of corn silk powder

Collecting stigma Maydis powder, rinsing, air drying, oven drying, mixing with acidic solution (containing citric acid and acetic acid) to dissolve to obtain stigma Maydis powder mixture, adding hydrogen peroxide for oxidative degradation, adjusting pH with sodium bicarbonate, and spray drying to obtain stigma Maydis powder.

Acquisition of zinc gluconate, selenium yeast and vitamin A

The ZINC GLUCONATE is available from ZINC GLUCONATE (14% ZINC) available from yun corporation, vitamin a is also available from powdered vitamin a (available from fuxin technologies, inc.) and the selenium yeast is available from wegian corporation, U.S.A..

Preparation of bitter tea oil

Baking bitter tea seeds, cooling the bitter tea seeds by a cooling tank, crushing the bitter tea seeds into powder, boiling and sterilizing the powder in a pot, taking out the powder and pressing the powder into cake shape, then applying pressure to the cake-shaped bitter tea seeds, cold pressing the bitter tea oil cake at low temperature until oil is fully squeezed out, and obtaining the bitter tea oil after precipitation and filtration.

In addition, the Marigold powder in the pharmaceutical composition of the present invention contains a xanthophyll, and the plant which is found to be most rich in xanthophyll is Marigold (Marigold, also known as Marigold), wherein the xanthophyll and Zeaxanthin contained in Marigold are both a similar Carotene (Carotene) which cannot be synthesized by human body and must be taken in food, and the xanthophyll can be found in the eyes, skin, cervix, heart and chest of human body, and is an important vitamin for maintaining the health of these parts, especially eyes, while the xanthophyll in the pharmaceutical composition of the present invention accounts for 0.3125% of the total amount of the components.

The present invention relates to a pharmaceutical composition, wherein the mulberry powder contains an anthocyanin, and it has been found that the mulberry (Bilberry) contains abundant anthocyanins (anthocyanodes), and the anthocyanins contained in the mulberry have strong antioxidant effect, and also have the ability of protecting blood capillary, improving eye fatigue, improving night vision, and accelerating the regeneration of rhodopsin, so that the pharmaceutical composition is widely used for eye health care, and the content of the anthocyanins in the pharmaceutical composition is 0.25%.

Furthermore, the red algae powder in the pharmaceutical composition of the present invention contains astaxanthin, and it is found that red algae contains abundant nutrition value, and the general environment is green, but when meeting the difficult environment such as strong ultraviolet irradiation or insufficient nutrition, the existing natural development can synthesize astaxanthin to make the body red to protect oneself.

Wherein, the pharmaceutical composition of the invention further comprises a cocoa powder (available from Fissistigment Oldhamii Co., Ltd.), a microcrystalline cellulose (available from Maoyi Co., Ltd.) and a magnesium stearate (available from Shunqing practice Co., Ltd.), further the cocoa powder accounts for 10% of the pharmaceutical composition of the invention, the microcrystalline cellulose accounts for 19.407% of the pharmaceutical composition of the invention, and the magnesium stearate accounts for 0.5% of the pharmaceutical composition of the invention.

Examples of the experiments

Grouping animals

Next, the present invention uses six-week-old ICR female mice as experimental animals, and divides the ICR female mice into five groups, wherein the grouping manner and experimental results are as follows, please refer to fig. 1A, which is a schematic diagram of changes in ocular distance according to an embodiment of the present invention, fig. 1B, which is a schematic diagram of detailed results of changes in intraocular pressure according to an embodiment of the present invention, and fig. 2, which is a long-strip schematic diagram of ocular distance corresponding to different experimental conditions according to an embodiment of the present invention:

(1) a normal control group (refer to Blank indicated in fig. 1 and 2, and referred to as Blank group);

(2) a group of drugs (referred to as Damage group, denoted in fig. 1B and 2) that does not use intraocular pressure containing the pharmaceutical composition;

(3) a drug group containing the intraocular pressure of the pharmaceutical composition (referred to as Dose L group, indicated in fig. 1B and fig. 2) at a low Dose;

(4) a drug group (referred to as Dose H group, as shown in FIGS. 1B and 2) containing intraocular pressure of the pharmaceutical composition at a high Dose; and

(5) the group of commercially available sulbactam solutions (referred to as LAP indicated in fig. 1B and fig. 2, and referred to as LAP group) was used.

Tube feeding mode and experimental mode

ICR female mice were illuminated with LED 24 hours a day for all groups from day 1 to day 16.

Dose L group: the intraocular pressure of the drug composition was adjusted to 64.5mg/kg by tube feeding ICR female mice with the drug composition on day 7 in addition to the LED light irradiation of the eyes.

Dose H group: the group containing the intraocular pressure of the pharmaceutical composition was administered with a high dose of a drug containing the intraocular pressure of the pharmaceutical composition on day 7, in addition to the LED light irradiation of the eyes, 129mg/kg of the drug containing the intraocular pressure of the pharmaceutical composition was additionally added to the ICR female mice fed by tube feeding.

LAP group: on day 7, in addition to the LED light illuminating the eyes, sulbactam (Latanoprost) ocular tension depressants were instilled into the eyes of ICR female mice once daily according to the instructions (50mcg/ml,2.5ml/bot, purchased from Perey pharmacia, one drop at a time, approximately 1.5 mcg/ml).

Results of the experiment

The intraocular pressure of the eyes of the 5 experimental groups was measured by an iCare TONOLAB tonometer instrument on

days

0, 3, 6, 10 and 16, the data of each group was measured 8 times and the average value thereof was taken to be listed in the statistical analysis, the statistical analysis was performed by using Paired sample t-test (Paired samples t-test) and Independent sample t-test (Independent samples t-test), and the difference between the front and rear of each group and the difference between the groups were measured, and the p value was 0.05, which is significant.

Referring to fig. 1A, 1B and 2, it is shown that the intraocular pressure increase induced by LED illumination for 24 hours is different from the rest four groups on day 3 in Blank group, and after confirming again that the intraocular pressure is high on day 6, intraocular pressure drugs (Dose L group and Dose H group) and sulbactam drop point (LAP group) of the pharmaceutical composition of the present invention are administered to the patient on day 7.

When the intraocular pressure was measured in each group of ICR female mice on day 10, it was found that the intraocular pressure was decreased in both the Dose L group, the Dose H group and the LAP group, and was significantly different from that in the Damage group, whereas the effect of relieving the intraocular pressure increase in the Dose H group was found to be effective on day 16.

While the LAP group was significantly different from the Damage group at day 10 and from the Blank group at day 16, and as shown in FIG. 1A, the LAP group definitely rebounded at day 16 after the LAP group declined at day 10, and thus it was observed that the eye drop of Shu and Tan used in the LAP group had the effect of relieving the increase in intraocular pressure but could not maintain the effect of reducing intraocular pressure.

Therefore, compared with sulbactam eye drops, the intraocular pressure relieving medicine of the medicine composition has better effect of relieving intraocular pressure increase than the commercial sulbactam eye drops, and has good relieving and preventing effects on injury caused by intraocular hypertension.

Therefore, it can be understood from the above results that the present invention is the use of a pharmaceutical composition for preparing a medicament for treating intraocular pressure, wherein natural substances such as wolfberry powder, chrysanthemum powder, mulberry powder, red algae powder, corn stigma powder, zinc gluconate, selenium yeast, bitter tea oil, vitamin a, marigold powder, etc. are used to replace traditional western medicines, so as to alleviate intraocular pressure increase (induced by LED lamp) and further alleviate symptoms of intraocular pressure increase.

The medicinal composition is used for preparing the medicine for treating intraocular pressure, which is different from the traditional western medicine, and because the medicinal composition in the invention is obtained from food or plants, no side effect is generated after the medicinal composition is used, and no physical burden is caused to a human body.

The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not intended to limit the scope of the present invention, which is defined by the appended claims.

Claims

1. The application of a pharmaceutical composition in preparing a medicine for treating intraocular pressure is characterized in that the pharmaceutical composition comprises a wolfberry fruit powder, a chrysanthemum flower powder, a mulberry fruit powder, a red algae powder, a corn stigma powder, zinc gluconate, selenium yeast, bitter tea oil, vitamin A and longspur inulin, and the pharmaceutical composition is used for relieving the symptoms of the intraocular pressure.

2. The use of the pharmaceutical composition of claim 1 for the preparation of a medicament for treating intraocular pressure, wherein the pharmaceutical composition further comprises a cocoa powder, a microcrystalline cellulose and a magnesium stearate.

3. The use of the pharmaceutical composition of claim 1 for the preparation of a medicament for treating intraocular pressure, wherein the marigold powder further comprises a xanthophyll.

4. The use of the pharmaceutical composition of claim 1 for the preparation of a medicament for treating intraocular pressure, wherein the powder of Morus bombycis further comprises an anthocyanin.

5. The use of the pharmaceutical composition of claim 1 for the preparation of a medicament for treating intraocular pressure, wherein the red algae powder further comprises astaxanthin.

6. The use of the pharmaceutical composition of claim 1 for the preparation of a medicament for treating intraocular pressure, wherein the pharmaceutical composition is for reducing an increase in intraocular pressure.

7. The use of the pharmaceutical composition of claim 6 for the preparation of a medicament for treating intraocular pressure, wherein the increase in intraocular pressure is induced by an LED lamp.